Status:
COMPLETED
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Lead Sponsor:
Alcon Research
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by poster...
Eligibility Criteria
Inclusion
- Clinical diagnosis of exudative AMD and a primary or recurrent (after laser photocoagulation) subfoveal choroidal neovascularization (CNV) lesion.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Less than 50 years of age.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00299507
Start Date
March 1 2005
End Date
April 1 2008
Last Update
November 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcon Study Sites
Fort Worth, Texas, United States, 76134